People search for a BPC-157 dose expecting a number. The honest answer is that no human dose has been established, and this page explains why, rather than repeating figures from seller protocols.
BPC-157 is a synthetic 15-amino-acid peptide whose sequence comes from a protein in human gastric juice. Most of what is written about it, including dosing, traces back to animal studies. This article was rewritten in October 2026; an earlier version listed protocols that we no longer consider supportable.
The published work is overwhelmingly preclinical: rats and mice with induced tendon, muscle, gut or nerve injuries, many of the studies from one research group. A 2025 review in Pharmaceuticals found the literature dominated by these animal models, with very little human data. Animal results are a reason to run human trials, not a substitute for them.
The figures that circulate (often expressed in micrograms, once or twice a day) are not taken from human trials, because there are no completed large ones. They are typically scaled down from animal doses, which is not a reliable way to set a human dose, or repeated from vendor and forum protocols. Two products sold under the same name may also contain different amounts, or something else entirely, because "research chemical" peptides are not regulated for purity.
FDA placed BPC-157 in Category 2 of its compounding bulk-substance list in 2023 over immunogenicity and impurity concerns. It came off that list in April 2026 after its nominations were withdrawn. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding it to the list of substances pharmacies may compound, against the recommendation of FDA's own staff. That vote is advisory. As of October 2026 FDA has not finalized it, BPC-157 is not an approved drug, and it remains prohibited in sport. If FDA does list it, any compounded prescription would come with a dose set by the prescriber, not by this site.
For a compact summary of evidence, risks and status, see the BPC-157 profile in our Peptide Guide.
There isn't one for humans. No completed large human trial has established a safe and effective dose; figures online come from animal extrapolation or seller protocols.
It is not FDA-approved. An advisory committee recommended in July 2026 that pharmacies be allowed to compound it, but FDA had not finalized that as of October 2026.
Because the numbers were not backed by human evidence. We would rather explain what is unknown than present guesses as a standard.